Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End

Executive Summary

Baxter, Ariad, Diurnal. Kyowa Kirin and AB Science are among the companies that will likely shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are under review.


Related Content

Ocrevus Tries Again For EU Approval Nod
Helsinn And AB Science Persevere In EU Despite CHMP Setback
FDA Approval Round Up: Keytruda, Opdivo Add Claims
Manufacturing Snag May Stall Portola's Bevyxxa Launch
Keeping Track: Breakthrough Therapies Becoming Breakthrough Applications For Tezacaftor, Burosumab, Emicizumab
Brigatinib Approval Validates Ariad Buy, But Can Takeda Carve A Position?
Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU
Hypogonadism Trial Designs: FDA Panel Favors Symptom Assessments, Fertility Measures
Diurnal Nears Market With Novel Adrenal Insufficiency Products
Repros Therapeutics Needs New Pivotal Trial For Low T Drug Enclomiphene


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts